I'll review the Stage 89 plan. Let me read all the relevant files in parallel.
I have all the context needed. Here are my rereview findings.

---

# Stage 89 Plan Rereview — Findings

## Critical

None.

## Important

None. Prior I-1 is resolved.

## Minor / Informational

### M-1. Commit message still omits stage context (carry-over from first review M-3, non-blocking)

`docs/superpowers/plans/2026-06-18-stage-89-review-protocol-code-record-plan.md:192` — `git commit -m "Document code review record names"`. Recent project commits typically carry stage context. Optional polish only; does not block implementation.

---

# Verification Of Applied Fixes

### Prior I-1 — Resolved via explicit carry-forward documentation

The design and plan now both contain the carry-forward note recommended in I-1 fix-option 2:

- `docs/superpowers/specs/2026-06-18-stage-89-review-protocol-code-record-design.md:50-55` — explicitly states Stage 89 continues to use `opencode-stage-89-*`, names the cause (current user-directed runner is local opencode), frames the runner drift as carry-forward, and states it is "not an attempt to label opencode output as Claude Code output."
- `docs/superpowers/plans/2026-06-18-stage-89-review-protocol-code-record-plan.md:26-34` — dedicated "Carry-Forward Review Runner Drift" section that says "Do not rename opencode-generated artifacts to `claude-code-stage-89-*`" and separates the naming-section alignment work from the runner-drift carry-forward.

This satisfies the prior review's recommended fix (option 2: document the drift as carry-forward). The note is also correctly placed outside the scanned `ACTIVE_REVIEW_DOCS` set (`AGENTS.md`, `REVIEW_PROTOCOL.md`, `docs/github-upload-checklist.md`), so it does not trigger `FORBIDDEN_ACTIVE_REVIEW_TERMS` in `tests/test_review_protocol_docs.py:16-22,29-38`.

---

# Answers To Rereview Questions

**1. Is prior Important finding I-1 resolved by explicit carry-forward documentation under the current user-directed opencode runner constraint?** — Yes. Both the design (`:50-55`) and the plan (`:26-34`) now explicitly acknowledge the persistent `opencode-stage-89-*` artifact drift as carry-forward under the local opencode runner, distinguish it from the checked-in Claude Code protocol naming work this stage performs, and instruct implementers not to rename opencode output. This is exactly the option-2 fix the first review recommended.

**2. Are the strengthened test-order assertions and `During Development` cross-reference correct and scoped?** — Yes to both.
   - Test ordering: `docs/superpowers/plans/2026-06-18-stage-89-review-protocol-code-record-plan.md:63-87` now asserts both presence and strict ordering (`plan < code < release`) within each of the review and rereview tuples. The order matches the doc ordering produced by Task 3 (`:122-127`, `:138-142`). The six names are distinct (no substring-collision risk that would distort `protocol_text.index(...)`), and the assertions do not mention `opencode-*`, so they do not overreach into historical records. This resolves first-review M-1.
   - Cross-reference: `:100-112` updates "During Development" step 2 to `Local Claude Code review of newly added code (docs/reviews/claude-code-stage-N-code-review.md).`, giving bidirectional alignment between the procedural step and the naming section. Correctly scoped (does not add a rereview step that the protocol does not already have; the code-rereview naming is covered by the naming-block update alone). This resolves first-review M-2.
   - The replaced assertions correctly target only the two prior direct checks at `tests/test_review_protocol_docs.py:49-50`; the other assertions in the same test (`:46-48,51`) are untouched.

**3. Are there any remaining Critical or Important blockers before implementation?** — No. No Critical findings, no Important findings. I-1 is resolved; M-1/M-2 from the first review are resolved by the strengthened test and the cross-reference. The only remaining note is M-1 above (commit message stage context), which is Minor/optional.

---

Proceed to implementation. Per `AGENTS.md`, the plan is acceptable on rereview.
